RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system
blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain…

Heart failure is a global pandemic affecting an estimated 26 million people worldwide and
resulting in more than 1 million hospitalizations annually in both the United States and Europe…

Little is known about specific modes of death in patients with heart failure with preserved
ejection fraction (HFpEF). Herein, the authors critically appraise the current state of data and …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization
for heart failure and cardiovascular death among patients with chronic heart failure …

Background Three drug classes (mineralocorticoid receptor antagonists [MRAs],
angiotensin receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …

With a prevalence of 5.8 million in the United States alone, heart failure (HF) is associated
with high morbidity, mortality, and healthcare expenditures. Close to 1 million hospitalizations …

Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …

PUBLISHED BY ELSEVIER levels stratified by age and sex. Estimates of several summary
epidemiological measures are produced, including composite measures such as …

Methods| Trends in mean weekly prescriptions dispensed between February 16 and April 25,
2020, of hydroxychloroquine/chloroquine, azithromycin, and the top 10 drugs based on …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …